BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 1, 2013
View Archived Issues
New antiviral agents prepared by GlaxoSmithKline
Read More
Jazz Pharmaceuticals announces licensing agreement
Read More
Vertex begins pivotal phase III lumacaftor/ivacaftor study
Read More
Ampio Pharmaceuticals begins Optina trial in diabetic macular edema
Read More
Inviragen advances DENVax into second stage of phase II trial
Read More
Lupin prepares new agents for HCV infection
Read More
SB-010 proves to be well tolerated in three distinct phase I trials
Read More
Takeda and Resolve Therapeutics enter partnership
Read More
Team describes methods to derive toolboxes of macrocyclic compounds
Read More
Vildagliptin approval expanded in Japan
Read More
Biosimilar of filgrastim approved in Japan
Read More
Novel coagulation factor XIa inhibitors patented by Bristol-Myers Squibb
Read More
Dainippon Sumitomo Pharma obtains additional indication approval for Surepost in Japan
Read More
HanAll BioPharma presents new AMPK activators
Read More
QRx Pharma resubmits MoxDuo NDA to the FDA
Read More
Ventana and Biocare Medical sign license agreement for diagnosis of prostate lesions
Read More
Burkholderia mallei mutant shows promise as a live attenuated vaccine
Read More
Korean group prepares novel 11-beta-HSD-1 inhibitors
Read More
ViiV Healthcare grants voluntary license to increase access to HIV medicine for children
Read More
Ceptaris resubmits NDA for proprietary gel formulation of chemotherapeutic agent
Read More
Immune response to intradermal flu vaccine evaluated in patients with atopic dermatitis
Read More
Sylentis commences phase II trial with SYL-1001
Read More
European Commission approves Ilaris in acute gouty arthritis indication
Read More
FDA approves once-monthly intramuscular depot formulation of aripiprazole
Read More
Hyperion's Ravicti now available in U.S.
Read More
Lundbeck's Selincro approved in E.U. for alcohol dependence
Read More